NasdaqGS:BBIOBiotechs
BridgeBio Pharma (BBIO): Negative Equity Underscores Balance Sheet Risk Despite Forecasted Profit Growth
BridgeBio Pharma (BBIO) remains unprofitable, with net losses having grown at an annual rate of 7.3% over the past five years. While the company’s net profit margins have yet to improve, forecasts point to rapid earnings growth ahead as analysts expect earnings to jump 73.17% per year and see BridgeBio turning profitable within three years. Revenue is also projected to accelerate by 42.8% per year, far outpacing the 10.3% growth rate forecast for the broader US market.
See our full analysis...